Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new way to treat immune‑driven disease

Autoimmune and inflammatory diseases arise when the immune system becomes misdirected, attacking the tissues it is meant to protect. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Christine Brown, PhD
Heritage Provider Network Professor in Immunotherapy, Deputy Director, T Cell Therapeutics Research Laboratories, City of Hope
Enrique Montero, MD, PhD
Research professor, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope
Table of Contents

YOU MAY BE INTERESTED IN

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
Christine Brown, PhD
Heritage Provider Network Professor in Immunotherapy, Deputy Director, T Cell Therapeutics Research Laboratories, City of Hope
Enrique Montero, MD, PhD
Research professor, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login